Company intelligence / Profile preview
Equilibra Bioscience LLC
- Ownership
- Private
- Development stage
- Phase 1
Overview
SR-604, their lead candidate, is in Phase I clinical trials for Hemophilia A. According to GlobalData, Phase I drugs for Hemophilia A have a 97% phase transition success rate for progressing into Phase II[2].
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Equilibra Bioscience LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equilibra Bioscience LLC.